A Phase 1/2a, Multicenter, Randomized, Controlled, Single-Blind, Dose-Finding Study to Evaluate the Safety and Efficacy of Cryopreserved Devitalized Adipose Tissue Allograft (BRC-OA) for Pain Treatment in Subjects With Mild to Severe Osteoarthritis (OA) of the Knee
Latest Information Update: 13 Apr 2026
At a glance
- Drugs BRC OA (Primary)
- Indications Osteoarthritis; Pain
- Focus Adverse reactions; Therapeutic Use
- Sponsors Britecyte
Most Recent Events
- 07 Apr 2026 Planned End Date changed from 1 Apr 2026 to 1 Aug 2026.
- 07 Apr 2026 Status changed from recruiting to active, no longer recruiting.
- 13 May 2025 Status changed from not yet recruiting to recruiting.